Merck Extends Galapagos Discovery Deal

According to this article in Fierce Biotech Merck has decided to extend its research collaboration with Galapagos. The agreement earlier this year called for Galapagos to be responsible for the discovery and development of small molecule candidate drugs for atherosclerosis therapies. This extension shows Merck's commitment to fighting both cardiovascular and metabolic diseases. Read the full article here.

Share this article with your social network, just click below to share now!

Share |